{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-general-issues/management/covid-19/","result":{"pageContext":{"chapter":{"id":"ebf47616-75d7-59cd-970d-a655e2243215","slug":"covid-19","fullItemName":"Scenario: COVID-19","depth":2,"htmlHeader":"<!-- begin field 4bf7cf63-a523-4cae-a0a0-ab950099055b --><h2>Scenario: COVID-19 Management</h2><!-- end field 4bf7cf63-a523-4cae-a0a0-ab950099055b -->","summary":"Covers management when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item b4ef87dc-5017-4131-80de-ab95009904ee --><!-- begin field 0d092208-6592-40b6-93c4-acbc01570d9d --><p>From birth onwards.</p><!-- end field 0d092208-6592-40b6-93c4-acbc01570d9d --><!-- end item b4ef87dc-5017-4131-80de-ab95009904ee -->","topic":{"id":"6af6d7dc-387f-54ef-a47e-e93bb9b41afc","topicId":"8ba62370-04a3-45cc-961c-5818175f72b5","topicName":"Palliative care - general issues","slug":"palliative-care-general-issues","lastRevised":"Last revised in August 2020","chapters":[{"id":"726a141d-557b-508d-89f5-deae60fc7fea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a91ad781-24da-5823-9793-a3c1d74e4c2b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f704a6f9-856d-5866-94e9-7d652f387c29","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6ee6d08e-38e5-5729-bebd-8ff6a35adf66","slug":"changes","fullItemName":"Changes"},{"id":"ecb7626b-f8cb-51f0-bce0-51e89ef2c29c","slug":"update","fullItemName":"Update"}]},{"id":"ba971990-214e-5a07-b261-32e33d55863c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"13a1a1f9-758d-5ead-b2ce-47ceddde60a4","slug":"goals","fullItemName":"Goals"},{"id":"81ab883c-26bf-5233-8593-cd8cbe2b5905","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"19818561-b69f-573c-9b92-db90a5f813ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"451dbe0b-b396-5953-a832-5052fdf579f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5c0044e-1140-59a6-99dc-c687169a8b21","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b6722865-51a8-5415-85d9-c8791b4f564f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"51f0b013-6d7f-59d6-93c4-90e63b6dc7e4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"72302acd-6918-5bd0-964a-3828f58f2ff0","slug":"definition","fullItemName":"Definition"}]},{"id":"9601bdaa-249b-5d5a-a63d-ac551f7c947b","fullItemName":"Management","slug":"management","subChapters":[{"id":"244018a3-b37c-527c-8687-6a4c6dd4e21b","slug":"management-approach","fullItemName":"Scenario: Management approach"},{"id":"01b6e7ce-3802-5f92-9eb6-44a866ab8da8","slug":"terminal-phase","fullItemName":"Scenario: Terminal phase"},{"id":"d0b16037-4b86-5e8d-b77f-e3afa445fd87","slug":"communication","fullItemName":"Scenario: Communication"},{"id":"ebf47616-75d7-59cd-970d-a655e2243215","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"a1e0eb3f-ee3b-5d3b-803a-2fdab771333b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"44a3d382-db4d-57b8-b63a-75783a45d837","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5fcf5384-ba61-5096-8325-0cc7528d9e45","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"637cc40d-ade0-53f7-94a8-40a53f7691dc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0896ded8-272d-528a-84c6-49f8622628d2","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"872e87d1-f6fb-56f8-8440-6800ed1401d0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"53e5cb0b-ed32-599d-91f6-e131be9b6c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f9e33c6f-8b0a-58cc-8e05-24821125ace1","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9601bdaa-249b-5d5a-a63d-ac551f7c947b","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"fdfe8265-1fe2-5b00-a7d0-9437da755cfa","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 27e2beab-6316-4067-80cf-ab9500990564 --><h3>Scenario: How should my management vary when considering the possibility of COVID-19?</h3><!-- end field 27e2beab-6316-4067-80cf-ab9500990564 -->","summary":null,"htmlStringContent":"<!-- begin item 60f9d941-ff6a-4f64-a40a-ab9500990564 --><!-- begin field bc8cc65e-8741-4218-b4cd-ab9500990564 --><h4>General advice</h4><ul><li>When managing a person who is in the palliative or terminal phase of their illness with COVID‑19 like symptoms, take into account:<ul><li>That not all people with these symptoms will have COVID‑19.</li><li>The person's underlying health conditions, severity of the acute illness, and if they are taking multiple medicines.</li><li>That older people with comorbidities, such as chronic obstructive pulmonary disease (COPD), asthma, hypertension, cardiovascular disease and diabetes have a higher risk of deteriorating and may need additional monitoring or more intensive management, including hospital admission, if this is appropriate to their phase of illness.</li><li>That patients with severe symptoms of COVID‑19 may deteriorate rapidly and need further assessment if this is appropriate to their phase of illness.</li></ul></li></ul><h4>Symptom control</h4><p>There are separate CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-cough/\">Palliative care - cough</a>, <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-dyspnoea/\">Palliative care - dyspnoea</a> and <a class=\"topic-reference external-reference\" href=\"/topics/delirium/\">Delirium</a> please see these topics for more information.</p><ul><li>Fever<ul><li>Be aware that, on average, the fever associated with COVID-19 is most common 5 days after exposure to the virus.</li><li>If you suspect that the person has COVID-19 advise them to drink fluids regularly to avoid dehydration (no more than 2 litres per day).</li><li>Do not use antipyretics with the sole aim of reducing body temperature.</li><li>Advise people to take paracetamol if they have fever and other symptoms that antipyretics would help treat. </li><li>Tell them to continue only while the fever and the other symptoms are present. </li><li>NICE suggests that until there is more evidence, paracetamol is preferred to nonsteroidal anti-inflammatory drugs (NSAIDs) for people with COVID‑19. </li></ul></li></ul><h4>Anticipatory prescribing</h4><ul><li>When prescribing and supplying anticipatory medicines at the end of life:<ul><li>Take into account potential waste, medicines shortages and lack of administration equipment by prescribing smaller quantities or by prescribing a different medicine, formulation or route of administration when appropriate.</li><li>If there are fewer health and care staff you may need to prescribe subcutaneous, rectal or long-acting formulations, and carers or family members may need to administer them.</li><li>Consider different routes for administering medicines if the patient is unable to take or tolerate oral medicines, such as sublingual or rectal routes, or subcutaneous injections.</li></ul></li></ul><!-- end field bc8cc65e-8741-4218-b4cd-ab9500990564 --><!-- end item 60f9d941-ff6a-4f64-a40a-ab9500990564 -->","subChapters":[{"id":"fa036ff9-8403-511d-8152-09d1778e4fc9","slug":"basis-for-recommendation-142","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9eb6cba8-2efa-4055-a37c-ab9500990567 --><h4>Basis for recommendation</h4><!-- end field 9eb6cba8-2efa-4055-a37c-ab9500990567 -->","summary":null,"htmlStringContent":"<!-- begin item 1427bc7b-043f-4927-b33c-ab9500990567 --><!-- begin field d04b4b9f-98d9-4bc4-9e08-ab9500990567 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) <em>COVID-19 rapid guideline: m</em><em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">anaging symptoms (including at the end of life) in the community </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-general-issues/references/\">NICE, 2020b</a>]<em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">.</em><br></p><!-- end field d04b4b9f-98d9-4bc4-9e08-ab9500990567 --><!-- end item 1427bc7b-043f-4927-b33c-ab9500990567 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}